Drug Approval | December 16, 2021
U.S. FDA approves Bristol Myers Squibb’s Orencia
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
The platform’s technology works as a compression algorithm for molecular testing
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
This clinical study demonstrated that the 14-day regimen of ImmunoSEB and ProbioSEB CSC3 resolved post-Covid-19 fatigue symptoms and improved patients' functional status and quality of life
PPH is associated with almost 20 per cent of maternal mortality in India
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Subscribe To Our Newsletter & Stay Updated
